This article needs to be updated.(August 2021) |
Date | 29 December 2020 – present |
---|---|
Location | Argentina |
Cause | COVID-19 pandemic in Argentina |
Target | Immunisation of Argentines against COVID-19 |
The COVID-19 vaccination program in Argentina is an ongoing effort of mass immunization. Vaccination against COVID-19 began in Argentina on 29 December 2020 aiming at health professionals. Argentina struck a deal with the United Kingdom in November 2020 for a British made vaccine produced by the pharmaceutical company AstraZeneca and the University of Oxford. The vaccines are part of a deal where Argentina received 22.4 million doses. [1] During the first week, 39,599 doses were applied to health professionals. [2]
On 18 February 2021, vaccination on citizens aged over 70 began in the Province of Buenos Aires. Schools, among other sites, were used as temporary vaccination centres. [3]
During the first days of November, the government announced that will acquire during December 2020 and January 2021, 25 million of doses from the Russian vaccine Sputnik V after it would enter phase III. [4] [5] [6] Other vaccines such as the developed by University of Oxford and AstraZeneca, Pfizer, and China were also announced to be acquired eventually. [7]
On 22 December the flight that would bring the first doses of the Sputnik V vaccine to the country left for Moscow, [8] after negotiations began in early December. [9] 300,000 doses arrived on 24 December, [10] with the vaccination campaign beginning on 29 December. [11] The governor of the province of Buenos Aires, Axel Kicillof, was among the first to receive the vaccine. [12] One day later, the AZD1222 vaccine developed by University of Oxford and AstraZeneca was also approved in the country. [13]
On 29 May 2021, health minister Carla Vizzotti met with Cuban president Miguel Díaz-Canel to discuss the possibility of distribution of the still unapproved Cuban-made vaccine SOBERANA 02. [14] [15]
On July 17, 2021, 3.5 million doses of Moderna vaccines arrived at Argentina as part of donation from the United States. [16] Before that, on July 9, 2021, Argentina announced that it had procured 20 million doses from Moderna on its supply deal. [17]
The European Investment Bank is collaborating with the Argentinian government to provide the country with $100 million to assist in the acquisition of COVID-19 vaccinations and to deploy vaccination campaigns. [18]
Vaccine | Approval | Deployment |
---|---|---|
Pfizer–BioNTech | Yes | Yes |
Oxford–AstraZeneca | Yes | Yes |
Sputnik V | Yes | Yes |
Sinopharm BIBP | Yes | Yes |
Moderna | Yes | Yes |
Bharat Biotech | Yes | No |
CanSino | Yes [19] | No |
Vaccine | Type (technology) | Phase I | Phase II | Phase III |
---|---|---|---|---|
CureVac | RNA | Completed | Completed | In progress |
ReiThera | Viral vector | Completed | Completed | In progress |
The COVID-19 pandemic in Argentina is part of the worldwide pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2. As of 17 May 2024, a total of 10,131,586 people were confirmed to have been infected, and 130,857 people were known to have died because of the virus.
The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant and 61% against the Delta variant.
Sputnik V or Gam-COVID-Vac is an adenovirus viral vector vaccine for COVID-19 developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Russia. It is the world's first registered combination vector vaccine for the prevention of COVID-19, having been registered on 11 August 2020 by the Russian Ministry of Health.
The COVID-19 vaccination program in the Philippines was a mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the pandemic in the country. The vaccination program was initiated by the Duterte administration on March 1, 2021, a day after the arrival of the country's first vaccine doses which were donated by the Chinese government.
Carla Vizzotti is an Argentine physician specialized in vaccine-preventable diseases. She was the Secretary of Health Access and Vice Minister of Health in Argentina's Health Ministry, working under Minister Ginés González García, until February 2021. She served as Minister of Health from 2021 to 2023, following González García's resignation.
The COVID-19 vaccination campaign in Italy is a mass immunization campaign that was put in place by the Italian government in order to respond to the ongoing COVID-19 pandemic. It started on 27 December 2020, together with most countries in the European Union.
India began administration of COVID-19 vaccines on 16 January 2021. As of 4 March 2023, India has administered over 2.2 billion doses overall, including first, second and precautionary (booster) doses of the currently approved vaccines. In India, 95% of the eligible population (12+) has received at least one shot, and 88% of the eligible population (12+) is fully vaccinated.
A dispute broke out in January 2021 between the European Commission and the pharmaceutical company AstraZeneca AB about the provision of COVID-19 vaccines during the COVID-19 pandemic, and, in February, spilled out into a dispute over Article 16 of the Northern Ireland Protocol. Vaccination proceeded apace in the UK but more slowly in the EU, and by the end of March 2021, over 30% of the UK population had received at least one dose of vaccine compared to about 8% of the EU population. This was partly due to limited availability of the AstraZeneca vaccine in the EU. The World Health Organization and the European Medicines Agency continued to state that the vaccine was safe and effective. However, a representative of the European Medicines Agency said in June that vaccines based on the mRNA technology should be preferred if available for all age groups, including for the over 60s.
The Argentine COVID-19 vaccination scandal, known in Argentina as vacunatorio VIP, is a political scandal related to the application of COVID-19 vaccines in the Ministry of Health of Argentina to citizens who, due to the limitations established in the vaccination protocol, were not authorized to receive these vaccines yet.
COVID-19 vaccination in Botswana is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
The COVID-19 vaccination program in Colombia is an ongoing effort of mass immunization put in place by the Colombian government in order to respond to the ongoing COVID-19 pandemic. The virus causing COVID-19 was confirmed to have reached Colombia on 6 March 2020. Colombia's preparation and readiness for a vaccine program allowed it to join the first group of countries who received vaccines through COVAX. The first vaccine in Colombia was given to a nurse on 17 February 2021.
The COVID-19 vaccination in Vietnam is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 30 January 2021, vaccinations commenced on 8 March 2021, and will continue throughout the year with the goal of vaccinating 80% of the population by June 2022. The Sputnik V was later approved for use on 23 March 2021. The Sinopharm BIBP vaccine was approved for emergency use on 4 June 2021, while Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine and Janssen COVID-19 vaccine were approved on 12 June 2021, 29 June 2021, and 15 July 2021, respectively. Vietnam approved Abdala vaccine from Center for Genetic Engineering and Biotechnology on 18 September 2021, and Covaxin from Bharat Biotech on 10 November 2021.
COVID-19 vaccination in Mexico is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in South Korea is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
The COVID-19 vaccination in Indonesia is an ongoing mass immunization in response to the COVID-19 pandemic in Indonesia. On 13 January 2021, the program commenced when President Joko Widodo was vaccinated at the presidential palace. In terms of total doses given, Indonesia ranks third in Asia and fifth in the world.
COVID-19 vaccination in Nigeria is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Vaccination began on 5 March 2021. As of 28 February 2022, 17,914,944 people have received their first dose a COVID-19 vaccine, and 8,197,832 have received their second dose.
Sputnik Light is a single dose COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology. It consists of the first dose of the Sputnik V vaccine, which is based on the Ad26 vector, and it can be stored at a normal refrigerator temperature of 2–8 °C (36–46 °F). The institute says this version would be ideally suited for areas with acute outbreaks, allowing more people to be vaccinated quickly. It will also be used as a third (booster) dose for those who received Sputnik V at least 6 months earlier.
COVID-19 vaccination in Sri Lanka is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, in response to the ongoing pandemic in the country. As of late July, the Sinopharm BIBP vaccine accounted for 78% of the total 13.8 million vaccines obtained by Sri Lanka to date. The United States donated over 1.5 million Moderna vaccine through COVAX.
COVID-19 vaccination in Taiwan is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country.